Currently, gastrointestinal hormone glucagon like peptide-1 (GLP-1) has received significant attention in main-taining glucose homeostasis through mechanisms involving augmentation of insulin, inhibition of glucagon secretion and regulation of gut motility. Therefore, GLP-1 receptor agonist (GLP-1RA) turns to be one of the most promising hypoglycemic agents for the treatment of type 2 diabetes mellitus (T2DM) and obesity. However, the benefits of GLP-1 and GLP-1RAs are not limited to glucose control and weight loss. Here, we provide a concise overview of the roles of GLP-1 and GLP-1RAs in autoimmune disease, cardiovascular disease (CVD), diabetic kidney disease (DKD), diabetic foot ulcer (DFU), polycystic ovary syndrome (PCOS), and Alzheimer's disease (AD) as well as future challenges in this regard.(c) 2022 Elsevier Inc. All rights reserved.
基金：
National Natural Science Foundation of China [82070859, 81100581]; Tongji Hospital in HuaZhong University of Science and Technology [2201103295]; Bethune-Merck Diabetes Research Fund [2018]; Cardiac rehabilitation and metabolic therapy research fund
第一作者单位：[1]Huazhong Univ Sci & Technol, Tongji Hosp, Div Endocnnol, Wuhan 430030, Peoples R China[2]Branch Natl Clin Res Ctr Metab Dis, Hubei, Peoples R China
通讯作者：
通讯机构：[1]Huazhong Univ Sci & Technol, Tongji Hosp, Div Endocnnol, Wuhan 430030, Peoples R China[2]Branch Natl Clin Res Ctr Metab Dis, Hubei, Peoples R China
推荐引用方式(GB/T 7714)：
Shao Shiying,Zhang Xiaoling,Xu Qinqin,et al.Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities[J].PHARMACOLOGY & THERAPEUTICS.2022,239:doi:10.1016/j.pharmthera.2022.108270.
APA：
Shao, Shiying,Zhang, Xiaoling,Xu, Qinqin,Pan, Ruping&Chen, Yong.(2022).Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities.PHARMACOLOGY & THERAPEUTICS,239,
MLA：
Shao, Shiying,et al."Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities".PHARMACOLOGY & THERAPEUTICS 239.(2022)
：
医学